H.U. Group Holdings, Inc.

4544

JP3822000000

Healthcare Facilities & Services

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
2,396 ^JPY	-0.44%		+1.29%	-10.06%

Mar. 13	H.U Unit Fujirebio Diagnostics Partners Beckman Coulter in Neurodegenerative Diseases Field	MT
Mar. 13	Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics	CI

H.U. Group Holdings, Inc. Provides Dividend Guidance for the Fiscal Year Ended March 31, 2022

May 20, 2022 at 02:00 am EDT

H.U. Group Holdings, Inc. expects to pay an ordinary dividend of JPY 63 per share for the fiscal year ended March 31, 2022 as compared to JPY 94 per share paid a year ago.

Latest news about H.U. Group Holdings, Inc.

H.U Unit Fujirebio Diagnostics Partners Beckman Coulter in Neurodegenerative Diseases Field	Mar. 13	MT
Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics	Mar. 12	CI
H.U. Group Holdings Inc. and Fujirebio Announces the Availability of the Lumipulse G pTau 217 Plasma Assay for the Fully Automated LUMIPULSE G Immunoassay Systems	Dec. 22	CI
Japanese Shares Rebound After Inflation Data, BoJ Rate Outlook	Dec. 22	MT
H.U. Group to Issue Stock Options to Directors, Employees	Dec. 21	MT
H.U. Group to Grant Share Options to Staff	Nov. 19	MT
H.U. Group Holdings, Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024	Nov. 09	CI
H.U. Group Holdings, Inc.(TSE:4544) dropped from FTSE All-World Index	23-09-18	CI
H.U. Group Holdings' Fiscal Full-Year Profit Falls 47%	23-05-17	MT
H.U. Group Holdings, Inc. Announces Dividend for the Year Ended March 31, 2023, Payable on May 30, 2023; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024	23-05-16	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	23-05-16	CI
H.U. Group Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
H.U. Group Holdings, Inc. Announces Launch of the Fully Automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests	23-03-28	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2023	23-02-10	CI
H.U. Group Holdings, Inc. Provides Year End Dividend Forecast for the Fiscal Year Ending March 31, 2023	23-02-10	CI
H.U. Group Holdings, Inc. Provides Dividend Guidance for the Second Quarter-End and for the Full Year of Fiscal Year Ending March 31, 2023	22-08-15	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-08-15	CI
Japan Equities End Week Higher; W-Scope Zooms 12% on Securing Approval for Unit's Listing in Korea	22-06-24	MT
H.U. Group Unit to Acquire Biomarker Assays Developer for $42 million	22-06-24	MT
H.U. Group Holdings, Inc. Provides Dividend Guidance for the Fiscal Year Ended March 31, 2022	22-05-20	CI
H.U. Group Unit Designates Managing Director	22-04-25	MT
H.U. Group Holdings, Inc. Announces Board Changes	22-04-22	CI
H.U. Group Holdings, Inc. Announces Launch of Fully Automated Lumipulse G ß-Amyloid 1-42 and ß-Amyloid 1-40 Plasma Assays for Research Use Only	22-03-30	CI
Fujirebio Enters the Field of Fully Automated Blood-Based Alzheimer’s Disease Biomarker Testing with the Release of the Lumipulse® G Ptau 181 Plasma Assay for Research Use Only	22-03-01	CI
Chiome Bioscience Signs License Agreement with H.U. Group Unit for New Diagnostic Kit	22-02-16	MT

Chart H.U. Group Holdings, Inc.

Duration

Period

More charts

H.U. Group Holdings Inc, formerly Miraca Holdings Inc is a Japan-based holding company engaged in manufacture and sale of clinical test drugs, entrusted clinical examination and sterilization related business. The Company operates in four business segments. The Outsourced Clinical Testing segment accepts special tests from medical institutions. The Clinical Laboratory Medicine segment manufactures and sells clinical laboratory medicines and sells them to medical institutions and contract clinical laboratory companies. The Sterilization segment mainly entrusts the sterilization of medical equipment used for medical treatment in hospitals of large-scale hospitals and the related operations. The New Development & Others segment is involved in the homecare & welfare equipment business, self-medication & health insurance business, food & environment & cosmetics inspection business.

Sector

Healthcare Facilities & Services

Calendar

2024-05-09 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for H.U. Group Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2,406 JPY

Average target price

2,582 JPY

Spread / Average Target

+7.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
H.U. GROUP HOLDINGS, INC.	-10.06%	882M
SONIC HEALTHCARE LIMITED	-16.65%	8.34B
RADNET, INC.	+39.98%	3.59B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-32.00%	2.75B
SYNLAB AG	-7.88%	2.48B
DR. LAL PATHLABS LIMITED	-9.58%	2.32B
NEOGENOMICS, INC.	-13.29%	1.79B
FLEURY S.A.	-19.46%	1.54B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.57%	1.21B
METROPOLIS HEALTHCARE LIMITED	+9.70%	1.13B

Medical & Diagnostic Laboratories